GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and ...

A new biostatistical modeling approach has the potential to support health decisions by pinpointing where HIV is concentrated ...

For adults with virologically suppressed HIV-1, once-weekly oral islatravir-lenacapavir (ISL/LEN) is noninferior to ...

Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it ...

HYPERTENSION among adults receiving highly active antiretroviral therapy (HAART) was highly prevalent, affecting 47.4% of participants in a cross-sectional study conducted across three referral ...

Mayo Clinic researchers have identified a protein that cancer cells use to shut down the body's immune response, a discovery that could help scientists develop new treatments that make cancer ...

Gilead delivers strongest Q2 base business growth in 3 years, raises full-year HIV guidance, and showcases rapid uptake of Yeztugo and Trodelvy despite acquisition-related EPS drag.

Q2 2026 earnings call recap: raised HIV/PrEP outlook, Yeztugo momentum, Veklury reset, and deal-driven EPS hit.

Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend.

Q2 2026 Earnings Call August 4, 2026 4:30 PM EDTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...

Experts say messenger RNA (mRNA) vaccines do not alter DNA, contrary to social media posts that resurfaced the long-debunked ...

(Nasdaq: GILD) announced today its results of operations for the second quarter 2026. "Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven ...